DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Zendy

Joaquı́n Mateo | Zendy; Suzanne Carreira | Zendy; Shahneen Sandhu | Zendy; Susana Miranda | Zendy; Helen Mossop | Zendy; Raquel Pérez-López | Zendy; Daniel Nava Rodrigues | Zendy; Dan R. Robinson | Zendy; Aurelius Omlin | Zendy; Nina Tunariu | Zendy; Gunther Boysen | Zendy; Núria Porta | Zendy; Penny Flohr | Zendy; Alexa Gillman | Zendy; Ines Figueiredo | Zendy; Claire Paulding | Zendy; George Seed | Zendy; Suneil Jain | Zendy; Christy Ralph | Zendy; Andrew Protheroe | Zendy; Syed A. Hussain | Zendy; Robert J. Jones | Zendy; Tony Elliott | Zendy; Ursula McGovern | Zendy; Diletta Bianchini | Zendy; Jane Goodall | Zendy; Zafeiris Zafeiriou | Zendy; Chris T. Williamson | Zendy; Roberta Ferraldeschi | Zendy; Ruth Riisnaes | Zendy; Bernardette Ebbs | Zendy; Gemma Fowler | Zendy; Desamparados Roda | Zendy; Wei Yuan | Zendy; YiMi Wu | Zendy; Xuhong Cao | Zendy; Rachel Brough | Zendy; Helen N. Pemberton | Zendy; Roger A’Hern | Zendy; Amanda Swain | Zendy; Lakshmi P. Kunju | Zendy; Rosalind A. Eeles | Zendy; Gerhardt Attard | Zendy; Christopher J. Lord | Zendy; Alan Ashworth | Zendy; Mark A. Rubin | Zendy; Karen E. Knudsen | Zendy; Felix Y. Feng | Zendy; Arul M. Chinnaiyan | Zendy; Emma Hall | Zendy; Johann S. de Bono | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Author(s) -

Joaquı́n Mateo,

Suzanne Carreira,

Shahneen Sandhu,

Susana Miranda,

Helen Mossop,

Raquel Pérez-López,

Daniel Nava Rodrigues,

Dan R. Robinson,

Aurelius Omlin,

Nina Tunariu,

Gunther Boysen,

Núria Porta,

Penny Flohr,

Alexa Gillman,

Ines Figueiredo,

Claire Paulding,

George Seed,

Suneil Jain,

Christy Ralph,

Andrew Protheroe,

Syed A. Hussain,

Robert J. Jones,

Tony Elliott,

Ursula McGovern,

Diletta Bianchini,

Jane Goodall,

Zafeiris Zafeiriou,

Chris T. Williamson,

Roberta Ferraldeschi,

Ruth Riisnaes,

Bernardette Ebbs,

Gemma Fowler,

Desamparados Roda,

Wei Yuan,

YiMi Wu,

Xuhong Cao,

Rachel Brough,

Helen N. Pemberton,

Roger A’Hern,

Amanda Swain,

Lakshmi P. Kunju,

Rosalind A. Eeles,

Gerhardt Attard,

Christopher J. Lord,

Alan Ashworth,

Mark A. Rubin,

Karen E. Knudsen,

Felix Y. Feng,

Arul M. Chinnaiyan,

Emma Hall,

Johann S. de Bono

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1506859

Subject(s) - olaparib , poly adp ribose polymerase , prostate cancer , dna repair , polymerase , cancer research , parp inhibitor , medicine , oncology , prostate , dna , cancer , biology , genetics

Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research